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Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by progressive ﬁbrosis of the skin and visceral tissues
as well as a noninﬂammatory vasculopathy. Vascular disease in systemic sclerosis is a major cause of morbidity and mortality
among nonpregnant patients with SSc and is even a bigger concern in the pregnant SSc patient, as the underlying vasculopathy
may prevent the required hemodynamic changes necessary to support a growing pregnancy. Vascular manifestations including
scleroderma renal crisis and pulmonary arterial hypertension should be considered relative contraindications against pregnancy
due to the high associations of both maternal and fetal morbidity and mortality. In contrast, Raynaud’s phenomenon may actually
improve somewhat during pregnancy. Women with SSc who are considering a pregnancy or discover they are pregnant require
evaluation for the presence and extent of underlying vasculopathy. In the absence of signiﬁcant visceral vasculopathy, most women
with SSc can expect to have reasonable pregnancy outcomes.
1.Introduction
Systemic sclerosis (SSc) is a chronic autoimmune disorder
characterized by progressive ﬁbrosis of the skin and vis-
ceral tissues as well as a non-inﬂammatory vasculopathy
manifesting as Raynaud’s phenomenon, digital ulcerations,
pulmonary arterial hypertension, and scleroderma renal
crisis.Vasculardiseaseinsystemicsclerosisisamajorcauseof
morbidity and mortality among non-pregnant patients with
SSc. There are two main subsets of SSc: diﬀuse cutaneous
disease is characterized by cutaneous ﬁbrosis proximal to
the forearms and is associated with higher incidence of
scleroderma renal crisis and pulmonary ﬁbrosis; limited
cutaneous disease has more limited cutaneous involvement
to the distal extremities and face and is associated with
higher prevalence of digital ulcers and pulmonary arterial
hypertension.
Akin to many autoimmune diseases, SSc has a strong
female predominance, with an approximate female- to male-
ratio of 5:1 [1, 2]. SSc is a relatively rare disease, with a
prevalence in North America estimated to be approximately
49,000–55,000,between25and44per100,000persons[1,2].
Symptom onset of SSc usually begins in the 5th decade,
approximately 10 years prior to the mean age of menopause.
In more recent decades, many women have postponed
childbearing into their 30s and 40s for career and other
personalreasons.Forthisreason,thenumber ofwomenwho
develop SSc and have not yet completed their families and
may be considering pregnancy is likely to increase. When
counseling women with SSc who are considering pregnancy
or who discover a pregnancy, it is critical to understand the
potential vascular complications that may lead to adverse
pregnancy outcomes.
2.Normal Hemodynamic andVascular
Changes of Pregnancy
In order to accommodate the enlarging uterus and growing
fetus, a pregnant woman’s body must make numerous
physiologic hemodynamic changes. Many of these changes
involve changes in blood volume, vascular resistance, cardiac
output, and oxygen consumption. Most physiologic changes
begin early in gestation and peak by the late second trimester
of pregnancy. Although not deﬁnitive, it has been suggested
that an initial fall in systemic vascular resistance leads to the
other well-established vascular and hemodynamic changes2 International Journal of Rheumatology
of pregnancies [3]. Activation of the renin-angiotensin-
aldosterone system results in a 7-8 liter increase in total
body ﬂuid during gestation (distributed between maternal
intra- and extracellular spaces, fetus, and amniotic ﬂuid)
[4]. Cardiac output increases by 50% over the course of
pregnancy, with the majority of increase occurring within
the ﬁrst 8 weeks, followed by a gradual increase until
plateau mid-third trimester [5]. This is mediated by an
increase in both stroke volume early in pregnancy and
heart rate throughout pregnancy. During pregnancy, cardiac
output is preferentially distributed to the uterus, kidneys,
skin, and breast tissue and away from skeletal muscle [6].
The pulmonary system additionally undergoes signiﬁcant
physiologic changes during pregnancy. Pulmonary vascular
resistance decreases. Basal oxygen consumption increases
by 50mL/min by term, and alveolar ventilation increases,
lowering PCO2 by about 8 torr.
The exact mechanisms underlying the hemodynamic
changes during pregnancy remain to be completely under-
stood. An increase in prostacyclin in both the fetoplacental
tissues and maternal system plays a clear role in systemic
vasodilation; however, additional mediators are required to
explain the degree of reduction in vascular resistance [3].
Nitric oxide (NO) is likely candidate to play a signiﬁcant role
in the hemodynamic accommodations during pregnancy.
There appears to be a permanent basal activity of NO in
utero- and fetoplacental vasculature in pregnant women; the
trophoblast may be a signiﬁcant source of NO production
[3]. NO donors administered to women between 8 and
10 weeks gestation resulted in a further fall of peripheral
resistance [7]. Other studies have demonstrated a deﬁciency
of NO in pregnancy complications associated with defective
placental perfusion: preeclampsia and intrauterine growth
restriction [3]. In addition to the important roles of prosta-
cyclin and NO in the maintenance of low peripheral vascular
resistance, the maternal vasculature appears to be resistant to
the eﬀects of angiotensin II.
Physiologic hemodynamic changes are an integral part
of human pregnancy. In some cases, changes in vascular
blood ﬂow and decreased vascular resistance may lead to
improvementinmanifestationsofsystemicsclerosis.Inother
cases, an intrinsic inability to adapt to the necessary hemo-
dynamic changes in pregnancy, possibly due to underlying
vasculopathy of systemic sclerosis, may contribute to adverse
pregnancy outcomes including hypertensive disorders of
pregnancy and intrauterine growth restriction.
3. MaternalandFetal Outcomes of
the SSc Pregnancy
Given the prominent vasculopathy associated with SSc,
there is concern for an increased risk of adverse pregnancy
outcomes associated with vascular compromise or inability
to make appropriate hemodynamic adaptations to support
a pregnancy. Indeed, early reports suggested very high rates
of maternal death during pregnancy [8–11]. It is likely
for this reason that women with SSc in past decades had
been strongly advised against pregnancy and often counseled
to terminate pregnancies that have occurred [12]. More
recently, a series of retrospective and prospective studies
have provided more detailed analysis of pregnancy outcomes
and have demonstrated that, for most women with SSc,
pregnancy outcomes are reasonably good [13–18]. Reported
rates of early pregnancy loss of 14%–15% [13, 14]a r e
somewhat increased from the estimated 10% in the general
population. Late pregnancy losses were few, and generally
occurred in women with severe diﬀuse SSc [14, 16]. Preterm
delivery rates have ranged from 8%to40% [13, 14, 16]. The
majority of preterm deliveries were on or after gestational
age 34 [14]. Small for gestational age infants (<10th%
tile for gestational age) [19], ranged from 0% to 50% [2,
14, 16]. Cases of preeclampsia were isolated [14, 16]. It
must be remembered, however, that these studies reﬂect
the experience of approximately 200 patients followed at
tertiary-care centers over a period of 10 years. A population-
based study of pregnancy outcomes among women with
SSc in the United States that utilized administrative hospital
discharge databases identiﬁed 504 SSc women who delivered
between 2004 and 2006 [18]. This study found a 22.9% rate
of hypertensive disorders including preeclampsia, a four-
fold increased odds compared to the general population
(85% CI, 2.4–6.6). Similarly, a nearly four-fold increased
rate of intrauterine growth restriction was found. Overall,
the majority of patients with SSc appear to have reasonable
obstetricoutcomesalthoughwomenwithrapidlyprogressive
diﬀuse disease may be at higher risk for complications.
4. Scleroderma Renal Crisis
Scleroderma renal crisis, characterized by malignant hyper-
tension, proteinuria, acute renal failure, microangiopathic
changes, and the pathognomonic “onion skin” appearance
of renal arteries on pathology, is one of the most severe
complicationsofSSc[20].Aﬀecting5%–10%ofSScpatients,
renal crisis characteristically occurs in patients with rapidly
progressing diﬀuse skin disease of relatively recent onset.
Prior to the widespread use of angiotensin-converting
enzyme (ACE) inhibitors, renal crisis was one of the leading
causes of mortality. Many of the perinatal deaths reported
among SSc patients involved scleroderma renal crisis [7–10].
Even in more recent series, episodes of renal crisis during
pregnancy were reported. Steen et al. reported two cases
of scleroderma renal crisis in a retrospective study of 86
pregnancies occurring after the diagnosis of SSc [12]. Both
cases occurred abruptly in the third trimester of pregnancy
a n dr e s u l t e di np r e t e r md e l i v e r y .O n ew o m a nd e v e l o p e d
end- stage renal disease, and the other died from status
epilepticus. In a prospective study of 91 pregnancies, Steen
reported two additional cases of renal crisis [13]. Both
womenrequiredhemodialysisafterdelivery.Allofthesecases
occurred in women with early, rapidly progressive diﬀuse
disease. It remains unclear if rates of renal crisis are increased
in pregnant women compared to nonpregnant women with
severe diﬀuse disease. The severity of scleroderma renal crisis
during pregnancy with very high risks of maternal and
fetal morbidity and mortality and the beneﬁts of treatment
with ACE inhibitors to both mother and fetus if renalInternational Journal of Rheumatology 3
crisis is suspected are highly likely to outweigh the risks of
fetotoxicity associated with use [14, 21, 22].
Unfortunately, scleroderma renal crisis can be diﬃcult
todistinguishfrompreeclampsia(abruptonsethypertension
andproteinuria)inthepregnantSScpatient;bothconditions
carry a high risk of severe maternal and fetal complications
if not treated aggressively. In situations where the woman
has a history of renal crisis or is at high risk for developing
renal crisis (early rapidly progressive renal disease), an
immediate trial of ACE inhibitors may be indicated. In cases
of profound maternal or fetal distress, emergent delivery
may be the most appropriate option followed by initiation
of ACE inhibitor therapy. In this situation, the deﬁnitive
therapy for preeclampsia has been completed (delivery),
and ACE inhibitors can be instituted without concern of
risk of fetotoxicity of antenatal ACE inhibitor exposure
[21]. Renal biopsy may be indicated in cases where the
distinctionbetweenrenalcrisisandpreeclampsiaisnecessary
for management [23].
5. Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) has been increas-
ingly recognized as a major cause of morbidity and mortality
in the SSc population. Estimates of PAH in the SSc popu-
lation range from 7.85% to 26.7% [24, 25]. In contrast to
scleroderma renal crisis, PAH can occur with both limited
and diﬀuse cutaneous disease and may be more prevalent
in patients with limited cutaneous disease. PAH in SSc
is a result of long standing vasculopathy involving the
pulmonary arterial vasculature. Pulmonary arterioles exhibit
the same “onion skin” appearance as seen in renal crisis.
Symptom onset is often insidious, delaying diagnosis and
theintroductionofappropriatetherapy.Expertsrecommend
routine screening for PAH to ensure early diagnosis and
therapy in hopes of preventing remodeling and permanent
occlusion of the vessel lumen.
ItisclearthatwomenwithP AHareatextremelyhighrisk
for severe hemodynamic complications during pregnancy
as there is signiﬁcantly less reserve in the pulmonary
arterioles to reduce vascular resistance to accommodate the
increased blood volume and cardiac output that occurs
during pregnancy. Reports estimate a 36%–50% maternal
death rate in women with PAH, with the most vulnerable
period occurring with delivery and the ﬁrst two weeks
postpartum [26, 27]. A more recent study suggested a
slightly lower maternal death rate of 17%–33%, but this is
arguably still unacceptably high [28]. Death is usually due
to acute cardiovascular collapse. Rates of preterm delivery
withresultantneonatalmorbidityandmortalityaresimilarly
high in the PAH population. For all of these reasons, women
with known PAH should be strongly discouraged from
becomingpregnant;additionally,womenwithSSc(diﬀuseor
limited cutaneous disease) should undergo careful screening
for subclinical PAH when considering a future pregnancy.
NoninvasiveevaluationforPAHincludesanechocardiogram
looking for a pulmonary arterial pressure of >30mm Hg at
rest or an isolated reduced diﬀusion capacity (DLCO) in the
absence of restrictive lung disease on standard pulmonary
functiontesting [24,25].Furthermore,allcomplaints ofdys-
pnea in pregnant SSc patients should prompt an immediate
evaluation for development or worsening of PAH. Assessing
diﬀusion capacity using carbon monoxide is considered safe
during pregnancy [29].
If a woman with PAH discovers a pregnancy and wishes
tocontinuewiththepregnancyorifPAHisdiagnosedduring
an established pregnancy, careful hemodynamic monitoring
and comanagement with pulmonologists experienced with
PAH is essential. Case reports have described successful use
of epoprostenol and sildenaﬁl during pregnancy [24, 26–28,
30–32]. Anticoagulation with low-molecular-weight heparin
is recommended to reduce risk of thromboembolism [26],
a n ds o m eh a v es u g g e s t e du s eo fs u p p l e m e n t a lo x y g e nt o
maintain a PO2 greater than 70mm Hg [26]. Inhaled NO
has been used in extreme circumstances during labor and
delivery [26, 27].
Delivery is a period of extremely high risk in the
woman with PAH. Acute hemodynamic changes including
increase in cardiac output of 25%–50% during the second
stage of labor through delivery with the return of blood
volume from the uterus to the main circulation [26, 27].
Increased maternal mortality has been described with gen-
eral ansthesia [28]. The preferred mode of delivery remains
controversial: vaginal delivery is associated with less shifts
in blood volume but has a prolonged second stage of labor
and issues regarding increased pressure with contractions.
Cesarean delivery reduces the second stage of labor and
may be necessary in cases of extreme maternal or fetal
distress but increases risks of infection and thrombosis
[28].
6. RaynaudsPhenomenon and
Digital Ulceration
Of all vascular complications of SSc, Raynauds phenomenon
and digital ulcers are most likely to improve during preg-
nancy. Raynauds phenomenon is characterized by vascu-
lar hyperreactivity and vasospasm. However, when digital
vasculopathy becomes more ﬁxed, as is often the case in
SSc, chronic poor perfusion leads to digital ulceration.
Raynauds phenomenon tends to improve during preg-
nancy, only to worsen postpartum [15]. Less is known
about the development of or healing of digital ulcerations.
Improvements may be because the increased blood volume
and reduced systemic vascular resistance may improve
peripheral circulation. Return to pre-pregnancy hemody-
namics leads to return of baseline peripheral circulatory
complications. A study of pregnancy outcomes among
women with primary Raynauds phenomenon (without SSc
orotherconnectivetissuediseases)foundaslightlyincreased
risk of preterm delivery and smaller weights among full-
term infants [33] but concluded that these outcomes did
not have any adverse clinical signiﬁcance for mother or
infant. The study did not evaluate the course of Ray-
naud’s phenomenon during the pregnancy or postpartum
period.4 International Journal of Rheumatology
7.Decidual/PlacentalVasculopathy
Given the diﬀuse vasculopathy present in patients with SSc,
there are concerns that the same pathophysiologic changes
may occur in the placental vasculature. The higher rates
of prematurity and small for gestation age babies seen in
SSc pregnancies may be a direct result of placental vascular
insuﬃciency. Most studies did not examine placental tissue,
thus not allowing for direct correlation between placental
vascular abnormalities and adverse pregnancy outcomes.
Histopathologic examination of placentas from a limited
number of SSc pregnancies has been reported; all of which
reported normal placenta weight for gestational age [34–
36]. In one study of three placentas from SSc patients
(gestational age at delivery between 34 and 38 weeks) found
evidence of decidual vasculopathy with stomal ﬁbrosis and
infarcts in chronic villi despite an absence of reported
adverse pregnancy outcomes [33]. In another case of a
pregnancy SSc patient with intrauterine growth restriction
was found to have increased resistance in the umbilical
artery by dopper examination at 31-week gestational age.
Examination of the placenta after delivery at 37 weeks
found numerous placental infarcts, placental mesenchymal
dysplasia, decreased vascularity, and stromal ﬁbrosis all
consistent with decidual vasculopathy [35]. In the largest
study to date, 13 placentas from SSc patients were examined
and correlated with perinatal outcomes [36]. Five of 13
placentas demonstrated marked decidual vasculopathy, four
of which were associated with intrauterine fetal demise
between weeks 16 and 30. Chorioamnionitis and accelerated
placental maturation complicated the majority of other
placentas. These ﬁndings are similar to what is seen in preg-
nancies complicated by pregnancy-induced hypertension.
Indeed, in a nationwide study of pregnancy outcomes of
SSc patients, 23% carried a diagnosis of pregnancy-induce
hypertension [18]. Thus, placental abnormalities may be
present in SSc pregnancies, even in the absence of clinical
perinatal complications, and these abnormalities may be
moreseverecorrelatingwithperinatalgrowthrestrictionand
death.
8. Conclusion
Healthy pregnancies require extensive pulmonary, cardio-
vascular, and vascular changes to support the fetus during
development. An inability to accommodate such changes
due to preexisting pulmonary, cardiac, or vascular disease
may lead to pregnancy complications and an inability to
support the continuance of the pregnancy. Vasculopathy is a
prominent feature of SSc in general and may play an impor-
tant role in adverse pregnancy outcomes in women with
preexisting disease. Women with SSc who are contemplating
pregnancy or who discover an inadvertent pregnancy should
undergo a thorough evaluation for systemic and organ-
speciﬁc vasculopathy. Those with a history of scleroderma
renal crisis or pulmonary arterial hypertension (or patients
at high risk for developing these complications) are at the
highest risk for maternal and fetal death and other highly
morbid complications of pregnancy. Those with or at high
risk for renal or pulmonary arterial vasculopathy should be
strongly advised against becoming pregnant and to consider
termination if a pregnancy occurs. If a woman wishes to
continue with a pregnancy after appropriate counseling
of risks, aggressive monitoring and co-management with
experts in renal or pulmonary arterial disease is mandatory.
Medications such as ACE inhibitors and prostaglandins,
which can carry risks for congenital malformations or fetal
toxicity, need to be considered as the beneﬁts to both mother
and fetus may outweigh known risks of antenatal exposure.
Labor and delivery is a very vulnerable period in these
cases, and patients may require extended observation in the
hospital following delivery to watch for acute cardiovascular
collapse in cases of PAH.
However, if after thorough evaluation, a woman with SSc
does not appear to have vasculopathy of the internal organs,
pregnancy may be considered. Raynaud’s phenomenon
should not be considered a contraindication to pregnancy in
the absence of renal disease or PAH. With careful monitoring
by high-risk obstetrics, most women without advanced
vasculopathy can expect to have reasonable perinatal out-
comes although preterm delivery is common. Advances in
neonatology have helped improve the short- and long-term
outcomes of premature infants.
Whenever possible, placentas and umbilical cords should
be subject to histopathologic examination for evidence
of decidual vasculopathy and stromal ﬁbrosis. This will
hopefullyleadtobetterunderstandingoftheroleofplacental
vasculopathy in adverse pregnancy outcomes and may
additionally provide histopathologic clues to systemic or
organ- speciﬁc vasculopathy in SSc patients.
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